Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Dec;20(12):2198-200.
doi: 10.1038/mt.2012.241.

Still seeking an effective "one-two" malaria vaccine punch

Joseph D Smith  1 , Brandon K Sack
Affiliations
Comment

Still seeking an effective "one-two" malaria vaccine punch

Joseph D Smith et al. Mol Ther. 2012 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The malaria life cycle. The cycle consists of the following life stages: mosquito, pre-erythrocytic/liver, and blood. Plasmodium is primarily an intracellular parasite (in the liver and red blood cell, RBC), and the malaria parasite is only briefly extracellular when the sporozoite migrates from the dermal bite site to infect the hepatocyte and during replicative cycles of RBC invasion. Within the skin, sporozoites present a moving target migrating between and through host dermal cells, and then traverse a blood vessel to enter the blood circulation. Invasive merozoites that emerge from hepatocytes are encapsulated in host membrane (merosomes). This encapsulation may shield them from liver Kupffer cells and other immune effector mechanisms. Four vaccine targets—CSP, TRAP, MSP1, and AMA1—are expressed at different life stages (see text). The blood-stage antigens, MSP1 and AMA1, begin to be expressed in late liver stages when the blood-stage merozoites form. Some of the major antibody (Ab)-based and cellular immune mechanisms and effector cells at the liver and blood stages are illustrated. Most blood-stage vaccine efforts have focused on neutralizing Abs. Sheehy et al. evaluated a viral-vectored vaccine approach in the human malaria challenge model to stimulate both Ab-based and T-cell effector mechanisms and improve cross-stage immunity. IFN-γ, interferon-γ iNOS, inducible nitric oxide synthase.
See this image and copyright information in PMC

Comment on

References

    1. Sheehy SH, Duncan CJA, Elias SC, Choudhary P, Biswas S, Halstead FD.et al. (2012ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans Mol Ther 202355–2368. - PMC - PubMed
    1. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL.et al. (2002Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites J Infect Dis 1851155–1164. - PubMed
    1. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H.et al. (1991Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals Am J Trop Med Hyg 45539–547. - PubMed
    1. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB.et al. (2011Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity Science 334475–480. - PubMed
    1. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH., and, Harty JT. Superior antimalarial immunity after vaccination with late liver stage–arresting genetically attenuated parasites. Cell Host Microbe. 2011;9:451–462. - PMC - PubMed